课题基金 / 基金详情

Kentucky Center for Clinical and Translational Science

Kentucky Center for Clinical and Translational Science
肯塔基州临床和转化科学中心
批准号:
8637113
负责人:
Philip A Kern
金额:
$15.27万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-06-01 至 2016-02-29

项目摘要

项目成果

Philip A Kern的其他基金

相似基金

相关文献

中文摘要
翻译
在肯塔基州大学(英国),我们建立了临床和转化科学中心 (CCTS)作为临床和转化研究的家园。英国位于列克星敦,在西部边缘, 阿巴拉契亚中部是该国最贫困的地区之一,那里的贫富差距前所未有。 疾病和死亡率。这些差异中的许多都源于危险行为,如吸烟,吸毒, 和肥胖。在本提案中,我们的总体目标是改变 在英国的转化研究,这将导致更好的健康为阿巴拉契亚中部的人。科学 发现为改善护理提供了潜力,以社区为基础的研究对 通过更好地传播最佳医疗保健,促进健康。然而,科学发现往往不 到达社区,由于导航复杂的临床过程和 翻译研究在这次申请中,我们将充分利用我们在教育、基础和临床方面的优势, 科学,以及我们在实践和社区为基础的参与性研究的优秀计划。 这些努力将导致科学发现,将影响阿巴拉契亚农村社区的健康 在短期内,并为未来的管道做准备。为了实现这些目标,英国将成立一个 与位于西弗吉尼亚州亨廷顿的马歇尔大学合作,此外,我们会成立一个 阿巴拉契亚翻译研究网络不仅涉及马歇尔,而且还涉及俄亥俄州的CTSA 州立大学、辛辛那提大学、莫尔黑德大学和皮克维尔骨病学院 药这一网络对于进一步发展我们在以下方面的强大计划尤为重要: 社区参与式研究。为了帮助整合我们的努力,我们开发了一种创新的 一组教师催化剂,谁将建立合作团队科学计划的慷慨试点支持 资助将针对各个科学层面的新想法。新的CCTS计划在“药物开发”, “新方法”和“风险相关行为研究”将利用我们的优势, 具有不同专业领域的调查人员,并将更快地影响阿巴拉契亚山脉的健康 社区我们最近招募了一位生物医学信息学的新领导者,并投入巨资, 该计划将大大提高我们在CCTS中将数据转化为知识的能力。 通过这些举措,英国将履行其作为肯塔基州旗舰大学的使命,以改善健康的 中部阿巴拉契亚,从而增加了独特的价值,改善健康的国家。
英文摘要
At the University of Kentucky (UK), we have established the Center for Clinical and Translational Science (CCTS) as a home for clinical and translational research. UK is located in Lexington, on the western edge of mid-Appalachia, one of the poorest areas of the country, where there are unprecedented disparities in disease and mortality. Many of these disparities stem from risky behaviors, such as smoking, drug abuse, and obesity. In this proposal, our overarching goal is to transform the pace, effectiveness, and quality of translational research at UK which will result in better health for the people of mid-Appalachia. Scientific discovery offers the potential for improved care, with community-based research offering a faster impact on health through a better dissemination of optimal medical care. However, scientific discoveries often do not reach the community due to the many difficulties with navigating the complex process of clinical and translational research. In this application, we will capitalize on our strengths in education, basic and clinical sciences, as well as our outstanding programs in practice- and community- based participatory research. These efforts will result in scientific discovery that will impact the health of the Appalachian rural community in the near term, and prime the pipeline for the future. To accomplish these goals, UK will form a collaboration with Marshall University, which is 2 hr away in Huntington, WV. In addition, we will form an Appalachian Translational Reseach Network involving not only Marshall, but also the CTSAs at the Ohio State University, University of Cinncinati, Morehead University, and Pikeville School of Osteopathic Medicine. This network will be especially important in the further development of our strong programs in community based participatory research. To help integrate our efforts, we have developed an innovative group of faculty CATalysts, who will build collaborative team science programs backed by generous pilot funding that will target novel ideas at all levels of science. New CCTS programs in "Drug Development", 'Novel Methodologies", and "Risk-Related Behavior Research" will capitalize on our strengths, engage investigators with diverse areas of expertise, and will more quickly impact the health of the Appalachian community. We have recently recruited a new leader in Biomedical Informatics and have invested heavily in this program, which will greatly improve our ability to transform data into knowledge throughout the CCTS. Through these initiatives, UK will fulfill its mandate as Kentucky's flagship university to improve the health of Central Appalachia, and thereby add unique value to improvements in the health of the nation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mirabegron and tadalafil effectiveness for treatment of prediabetes
  • 批准号:
    10363388
  • 项目类别:
  • 资助金额:
    $30.6万
  • 财政年份:
    2021
  • 负责人:
    Philip A Kern
  • 依托单位:
Mirabegron and tadalafil effectiveness for treatment of prediabetes
  • 批准号:
    10532229
  • 项目类别:
  • 资助金额:
    $30.6万
  • 财政年份:
    2021
  • 负责人:
    Philip A Kern
  • 依托单位:
Mechanisms for activation of beige adipose tissue in humans
  • 批准号:
    10531210
  • 项目类别:
  • 资助金额:
    $60.91万
  • 财政年份:
    2020
  • 负责人:
    Philip A Kern
  • 依托单位:
Mechanisms for Activation of Beige Adipose Tissue in Humans; Supplement
  • 批准号:
    10630687
  • 项目类别:
  • 资助金额:
    $47.25万
  • 财政年份:
    2020
  • 负责人:
    Philip A Kern
  • 依托单位:
海外基金